OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Opthea Limited
- Study ID
- NCT04757636
- Phase
- PHASE3
- Status
- Terminated
Conditions
- Neovascular Age-related Macular Degeneration
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- 2.0 mg OPT-302 — BIOLOGICALintravitreal injection
- 2.0 aflibercept — BIOLOGICALintravitreal injection
- Sham — PROCEDUREintravitreal injection
Study Details
A 2-year phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.
Key Dates
- Start date
- Mar 12, 2021
- Status verified
- Jun 2025
- Primary completion
- Mar 31, 2025
- Completion
- Mar 31, 2025
Study Design
- Enrollment
- 998 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: 2.0 mg aflibercept with Standard Dosing 2.0 mg OPT-3022.0 mg aflibercept intravitreal injection administered at 4-weekly intervals for three treatments, and then at 8-weekly intervals. 2.0 mg OPT-302 intravitreal injection administered at 4-weekly intervals.
- Experimental: 2.0 mg aflibercept with Extended Dosing 2.0 mg OPT-3022.0 mg aflibercept intravitreal injection administered at 4-weekly intervals for three treatments, and then at 8-weekly intervals. 2.0 mg OPT-302 intravitreal injection administered at 4-weekly intervals for three treatments, and then at 8-weekly intervals, with sham intravitreal injection administered at visits when OPT-302 is not.
- Sham Comparator: 2.0 mg aflibercept with sham2.0 mg aflibercept intravitreal injection administered at 4-weekly intervals for three treatments, and then at 8-weekly intervals. Sham intravitreal injection administered at 4-weekly intervals.
Primary Outcome Measure
Mean Change in Early Treatment Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) Letters [ Time Frame: Baseline to Week 52 ]
Locations (60)
Find similar trials in Phoenix, AZ
Related Studies
- Extension Study for the Port Delivery System With Ranibizumab (Portal)PHASE3 · Recruiting · Hoffmann-La Roche · Phoenix, Arizona
- Long-term Follow-Up Study of RGX-314 and Fellow Eye SubstudyPHASE2 · Enrolling By Invitation · AbbVie · Phoenix, Arizona
- A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)PHASE4 · Recruiting · Genentech, Inc. · Mesa, Arizona
- Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMDPHASE3 · Recruiting · Jaeb Center for Health Research · Glendale, California